Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 274 of the 281 references it cites were found in a registry or an index; 135 of the 315 sources its claims cite were checked for support.

Multiple myeloma: signaling pathways and targeted therapy

Open access
Lu, Qizhong, Yang, Donghui, Li, Hexian, Niu, Ting, Tong, Aiping · 2024 · Molecular biomedicine

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of malignant plasma cells. The pathogenesis of MM involves the interaction between MM cells and the bone marrow microenvironment through soluble cytokines and cell adhesion molecules, which activate various signaling pathways such as PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways. Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma cells, making them attractive targets for therapeutic intervention. Currently, approved drugs targeting these signaling pathways in MM are limited, with many inhibitors and inducers still in preclinical or clinical research stages. Therapeutic options for MM include non-targeted drugs like alkylating agents, corticosteroids, immunomodulatory drugs, proteasome inhibitors, and histone deacetylase inhibitors. Additionally, targeted drugs such as monoclonal antibodies, chimeric antigen receptor T cells, bispecific T-cell engagers, and bispecific antibodies are being used in MM treatment. Despite significant advancements in MM treatment, the disease remains incurable, emphasizing the need for the development of novel or combined targeted therapies based on emerging theoretical knowledge, technologies, and platforms. In this review, we highlight the key role of signaling pathways in the malignant progression and treatment of MM, exploring advances in targeted therapy and potential treatments to offer further insights for improving MM management and outcomes.

Overview

CoChat Summary

## TL;DR

This review summarizes how dysregulated signaling pathways in multiple myeloma—especially PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB—drive proliferation, survival, migration, and drug resistance. It also surveys targeted therapies, highlighting approved and investigational monoclonal antibodies, ADCs, bispecific antibodies/BiTEs, CAR-T, CAR-NK, and TCR-T approaches, while emphasizing that MM remains incurable.

## Key findings

  • The paper states that MM is the second most common hematologic malignancy, accounting for about 10% of all hematological cancers, with an annual incidence of 4.5–6 per 100,000 and about 100,000 deaths worldwide each year.
  • It identifies five major signaling pathways implicated in MM pathogenesis: PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB; these pathways are described as promoting proliferation, survival, migration, and drug resistance.
  • For targeted immunotherapy, the review notes FDA/EMA-approved or FDA-approved agents including daratumumab, elotuzumab, isatuximab, teclistamab, elranatamab, talquetamab, Abecma, Carvykti, and others, with example efficacy figures such as teclistamab ORR 63.0% in 165 RRMM patients, elranatamab ORR 61.0% (75/123), and Abecma ORR 73% in 128 RRMM patients.
  • The review highlights the limitations of current targeted therapy: even with advances, overall survival curves have not reached a plateau, and resistance, relapse, adverse events, and access/cost remain major issues.

## Methods

  • This is a narrative review of MM biology and therapy, not an original clinical study.
  • It synthesizes published evidence on MM signaling pathways and targeted treatments, including clinical trial results, approved drugs, and preclinical studies drawn from the cited literature.
  • The main analysis is descriptive and comparative, organizing findings by pathway and therapy class rather than performing a new statistical meta-analysis.

## Limitations

  • The paper explicitly notes that approved drugs targeting these signaling pathways are limited, and many inhibitors/inducers remain in preclinical or clinical research stages.
  • The review states that targeted therapies still face high treatment costs, suboptimal PFS, relapse from resistance, and side effects such as CRS and neurotoxicity.
  • Evident from the text: because this is a review article, conclusions depend on the quality and heterogeneity of the cited studies; however, the paper does not state that it performed a systematic review or meta-analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s43556-024-00188-w

Cites

274 of 274 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Signaling pathways in the pathogenesis of multiple myeloma. Signaling pathways such as PI3K/AKT/mTOR, JAK/STAT, RAS/MAPK, Wnt/β-catenin and NF-κB pathway participate the pathogenesis of MM by mediating the proliferation, migration, expansion, survival, angiogenesis and drug resistance of MM cells
Fig. 1 Signaling pathways in the pathogenesis of multiple myeloma. Signaling pathways such as PI3K/AKT/mTOR, JAK/STAT, RAS/MAPK, Wnt/β-catenin and NF-κB pathway participate the pathogenesis of MM by mediating the proliferation, migration, expansion, survival, angiogenesis and drug resistance of MM cellsCC BY · PubMed Central
Fig. 2 Targeted immunotherapeutic in the treatment of multiple myeloma. Numerous novel targeted immunotherapies have been explored for the treatment of MM, including mAbs, ADCs, BsAbs, ICIs, CAR-T, CAR-NK and TCR-T cells. mAbs: monoclonal antibodies; ADCs: antibody-drug conjugates; BsAbs: bispecific antibodies; BiTEs: bispecific T-cell engagers; ICIs: immune checkpoint inhibitors; CAR-T: chimeric antigen receptor T; BCMA: B cell maturation antigen; GPRC5D: G protein-coupled receptor, class C, group 5, member D; FcRH5: Fc receptor-homolog 5; SLAMF7: SLAM Family Member 7; NKG2D: Natural-killer group 2, member D; PD-1: programmed cell death protein 1; PD-L1: programmed death-ligand 1
Fig. 2 Targeted immunotherapeutic in the treatment of multiple myeloma. Numerous novel targeted immunotherapies have been explored for the treatment of MM, including mAbs, ADCs, BsAbs, ICIs, CAR-T, CAR-NK and TCR-T cells. mAbs: monoclonal antibodies; ADCs: antibody-drug conjugates; BsAbs: bispecific antibodies; BiTEs: bispecific T-cell engagers; ICIs: immune checkpoint inhibitors; CAR-T: chimeric antigen receptor T; BCMA: B cell maturation antigen; GPRC5D: G protein-coupled receptor, class C, group 5, member D; FcRH5: Fc receptor-homolog 5; SLAMF7: SLAM Family Member 7; NKG2D: Natural-killer group 2, member D; PD-1: programmed cell death protein 1; PD-L1: programmed death-ligand 1CC BY · PubMed Central
Fig. 3 The mechanism of action underlying antibody-drug conjugates in the treatment of multiple myeloma. Circulated ADCs bind to MM cells surface antigens such as BCMA, CD138, CD38, FcRH5 and CD46 through monoclonal antibodies moiety. Bound ADCs are internalized into MM cells in the endosome. The ADC drugs are recycled out of MM cells or released from cleavable linker or digestion via fusion with lysosome. Released drugs induced cell apoptosis or death targeting microtubules or DNA
Fig. 3 The mechanism of action underlying antibody-drug conjugates in the treatment of multiple myeloma. Circulated ADCs bind to MM cells surface antigens such as BCMA, CD138, CD38, FcRH5 and CD46 through monoclonal antibodies moiety. Bound ADCs are internalized into MM cells in the endosome. The ADC drugs are recycled out of MM cells or released from cleavable linker or digestion via fusion with lysosome. Released drugs induced cell apoptosis or death targeting microtubules or DNACC BY · PubMed Central
Fig. 4 Schematic representation of the T-cell-engaging bispecific antibodies in the treatment of multiple myeloma. T-cell-engaging bispecific antibodies simultaneously bind to antigens on MM cells and CD3 subunits on T cells, leading to the recruitment of T cells to the MM cells, followed by activation, degranulation, and elimination of MM cells. BCMA: B cell maturation antigen; GPRC5D: G protein-coupled receptor, class C, group 5, member D; FcRH5: Fc receptor-homolog 5
Fig. 4 Schematic representation of the T-cell-engaging bispecific antibodies in the treatment of multiple myeloma. T-cell-engaging bispecific antibodies simultaneously bind to antigens on MM cells and CD3 subunits on T cells, leading to the recruitment of T cells to the MM cells, followed by activation, degranulation, and elimination of MM cells. BCMA: B cell maturation antigen; GPRC5D: G protein-coupled receptor, class C, group 5, member D; FcRH5: Fc receptor-homolog 5CC BY · PubMed Central

Verification

Claims the paper makes

91 Valid · 4 Not valid · 97 Not checked · 19 Own results and interpretations

101 more claims · 46 with their cited sources checked

Create a free account to see all 211 claims and to verify the 16 references still open.

See all claims — free account
  • It may state two separate claims as one. 104
  • Probably not a substantial claim. 6
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

2 of 2

Citations

Cites

2 retracted

Show all 281 references

Research works printed but not linked: 1

  1. GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma. 2023. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep/.

Cited by

See all 90

Metadata

Authors
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Northwest A&F University (CN)
  • Sichuan University (CN)
Corresponding author
  • Niu, Ting
  • Tong, Aiping
Venue
Molecular biomedicine
Published
2024-07-04
Volume
5
Issue
1
Pages
25-25
ISSN
2662-8651 (ISSN-L)
OpenAlex
W4400307776
Cited by
90
References
281
Citations by year
2026: 44 · 2025: 40 · 2024: 6
FWCI
7.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Biomedicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (82073404)
  • the 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYJC21003)
  • the Achievement Transformation Project (CGZH21001)
  • the Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation (TFJC2023010006)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
multiple myeloma, signaling pathways, targeted therapy, PI3K/AKT/mTOR pathway, RAS/MAPK pathway, JAK/STAT signaling, Wnt/β-catenin signaling, NF-κB signaling, bone marrow microenvironment, drug resistance, proteasome inhibitors, histone deacetylase inhibitors, immunomodulators, monoclonal antibodies, chimeric antigen receptor T cells, bispecific T-cell engagers, bispecific antibodies, malignant plasma cells
MeSH terms
Animals, Antineoplastic Agents, Humans, Multiple Myeloma, Signal Transduction, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiple myeloma: signaling pathways and targeted therapy. https://app.cochat.ai/papers/10.1186/s43556-024-00188-w
The paper
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024). Multiple myeloma: signaling pathways and targeted therapy. Molecular biomedicine. https://doi.org/10.1186/s43556-024-00188-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.